Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study

OBJECTIVES:Oral contraceptive (OC) use has been consistently linked to increased risk of inflammatory bowel disease. Nonetheless, a specific role of OC in the natural history of ulcerative colitis (UC) is unknown.METHODS:We identified 6,104 incident female UC cases aged 16–51 years at diagnosis from the Swedish National Patient Register starting in January of 2003. Information on current OC use was obtained from the Prescribed Drug Register starting in July of 2005. We followed cases through December of 2014 for primary outcome defined as first UC-related surgery, and the secondary outcomes defined by recipient of the first prescription of oral steroids or anti-tumor necrosis factor (anti-TNF) use. We used Cox proportional hazard modeling with time-varying covariates to estimate multivariable-adjusted hazard ratio (aHR) and 95% confidence interval (CI).RESULTS:Over 31,421 person-years of follow up, we observed 162 cases of UC-related surgery. Compared with nonusers, current and past use of OC were not significantly associated with risk of UC-related surgery (aHR=0.79; 95% CI, 0.52–1.18; and aHR=0.74, 95% CI, 0.46–1.18, respectively). The association did not appear to be modified by type of OC use (progestin-only vs. combination of progestin and estrogen), longer duration of use, or higher number of dispensed prescriptions (All Ptrend>0.28). Similarly, longer use or higher cumulative number of OC prescriptions were not associated with increased risk of receiving a steroid prescription (Ptrend=0.68 and 0.63, respectively). In exploratory analyses restricted to Stockholm county, current OC use was not associated with increased risk of receiving anti-TNF therapy (aHR=0.83, 95% CI, 0.59–1.18).CONCLUSIONS:In a large nationwide registry of UC patients, we found no association between OC use and UC progression. Our data offer reassurance regarding the safety of OC assessed by its effect on risk of surgery and steroid or anti-TNF use in women with established UC.

[1]  C. Mulder,et al.  Estrogen receptor-β signaling modulates epithelial barrier function. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[2]  S. Bonfils,et al.  Acute spontaneously recovering ulcerating colitis (ARUC) , 1977, The American Journal of Digestive Diseases.

[3]  K. Michaëlsson,et al.  Registers of the Swedish total population and their use in medical research , 2016, European Journal of Epidemiology.

[4]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[5]  Fraser Cummings,et al.  The pattern and outcome of acute severe colitis. , 2010, Journal of Crohn's & Colitis.

[6]  J. Ludvigsson,et al.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research , 2009, European Journal of Epidemiology.

[7]  R. Straub,et al.  Oestrogens in rheumatic diseases: friend or foe? , 2008, Rheumatology.

[8]  S. Ng,et al.  Geographical variability and environmental risk factors in inflammatory bowel disease , 2013, Gut.

[9]  M. Neovius,et al.  Association Between Long-term Oral Contraceptive Use and Risk of Crohn's Disease Complications in a Nationwide Study. , 2016, Gastroenterology.

[10]  F. Magro,et al.  Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. , 2015, Journal of Crohn's & colitis.

[11]  M. Neovius,et al.  Nationwide prevalence of inflammatory bowel disease in Sweden: a population‐based register study , 2014, Alimentary pharmacology & therapeutics.

[12]  J. Manson,et al.  Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. , 2012, Gastroenterology.

[13]  S. Truelove,et al.  The course and prognosis of ulcerative colitis , 1963, Gut.

[14]  P. Tekkis,et al.  The Risk of Oral Contraceptives in the Etiology of Inflammatory Bowel Disease: A Meta-Analysis , 2008, The American Journal of Gastroenterology.

[15]  M. Vatn,et al.  Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort , 2007, The American Journal of Gastroenterology.

[16]  A. Wiréhn,et al.  Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: A nationwide population-based study with age-specific analyses , 2012, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[17]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[18]  A. Ananthakrishnan,et al.  Oral contraceptives, reproductive factors and risk of inflammatory bowel disease , 2012, Gut.

[19]  V. Théodorou,et al.  Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats , 2009, Proceedings of the National Academy of Sciences.

[20]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[21]  A. Zinsmeister,et al.  Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[22]  A. Wiréhn,et al.  Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010 , 2013, BMJ Open.

[23]  B. Smedby,et al.  [Reliability of the hospital registry. The diagnostic data are better than their reputation]. , 1994, Lakartidningen.

[24]  L. Lissner,et al.  Evidence for a secular trend in menopausal age: a population study of women in Gothenburg , 2003, Menopause.

[25]  W. Willett,et al.  Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease , 2013, Gut.